Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study

Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors. The incidence of tac-DILI was 8.9% (95% CI = 7.2–10.7%). The most common type was cholestatic pattern (6.7%, 95% CI = 5.2–8.3%), followed by hepatocellular (1.6%, 95% CI = 0.8–2.4%) and mixed patterns (0.6%, 95% CI = 0.1–1.1%). 98.9% of recipients with tac-DILI have mild severity. The latency period were 42.0 (range, 21.5–99.8 days), 14.0 (range, 9.0–80.3 days), 16.0 (range, 11.5–24.5 days), and 49.0 days (range, 28.0–105.6 days) for total, hepatocellular, mixed, and cholestatic patterns, respectively. Baseline ALP level (OR = 1.015, 95% CI = 1.006–1.025, p = 0.002), age (OR = 0.971, 95% CI = 0.949–0.994, p = 0.006), and body weight (OR = 0.960, 95% CI = 0.940–0.982, p < 0.001) were independent risk factors. In conclusion, cholestatic pattern represents the most frequent type of tac-DILI. Young age, low body weight and abnormal baseline ALP level were risk factors.

[1]  Qingnan He,et al.  Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method , 2021, Frontiers in Pharmacology.

[2]  E. Porrini,et al.  Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update , 2021, Nephron.

[3]  G. Aithal,et al.  Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[4]  E. Björnsson,et al.  Drug-Induced Liver Injury - Types and Phenotypes. , 2019, The New England journal of medicine.

[5]  T. Karlsen,et al.  EASL Clinical Practice Guidelines: Drug-induced liver injury. , 2019, Journal of hepatology.

[6]  L. Butani Immunosuppressive Medications in Kidney Transplantation , 2018, Adolescents with Chronic Kidney Disease.

[7]  Jacqueline Corrigan-Curay,et al.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. , 2018, JAMA.

[8]  Q. Shi,et al.  Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status , 2017, International journal of toxicology.

[9]  C. Stephens,et al.  Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. , 2016, Journal of hepatology.

[10]  G. Danan,et al.  Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease , 2016, Drug Safety.

[11]  S. Abid,et al.  Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats , 2016, Journal of Physiology and Biochemistry.

[12]  William M. Lee,et al.  Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. , 2015, Gastroenterology.

[13]  I. Mahmood Prediction of drug clearance in children: a review of different methodologies , 2015, Expert opinion on drug metabolism & toxicology.

[14]  R. Fontana,et al.  Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. , 2014, Journal of hepatology.

[15]  P. Kes,et al.  Rescue therapy with sirolimus in a renal transplant recipient with tacrolimus-induced hepatotoxicity , 2013, Renal failure.

[16]  S. Min,et al.  Conversion of Twice‐Daily Tacrolimus to Once‐Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  G. Gores,et al.  Frequency, clinical presentation, and outcomes of drug‐induced liver injury after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  M. Schuemie,et al.  Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. , 2010, British journal of clinical pharmacology.

[19]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[20]  Y. Mizuguchi,et al.  Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. , 2008, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[21]  Sh Zhongyang,et al.  A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. , 2007, Transplantation proceedings.

[22]  E. Björnsson,et al.  Long‐term follow‐up of patients with mild to moderate drug‐induced liver injury , 2007, Alimentary pharmacology & therapeutics.

[23]  P. Kuo,et al.  One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  R. Andrade,et al.  Outcome of acute idiosyncratic drug‐induced liver injury: Long‐term follow‐up in a hepatotoxicity registry , 2006, Hepatology.

[25]  J. Chapman,et al.  The natural history of chronic allograft nephropathy. , 2003, The New England journal of medicine.

[26]  S. Jensik,et al.  Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1 , 2003, Transplantation.

[27]  G. Anderson Children Versus Adults: Pharmacokinetic and Adverse‐Effect Differences , 2002, Epilepsia.

[28]  E. Wijdicks Neurotoxicity of immunosuppressive drugs , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[30]  J. Pirsch,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.